Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar Cholangiocarcinoma

Completed

• Conditions: Portal Vein Embolization; Biliary Tract Cancer
• Interventions: Procedure: Potal vein embilization

• Registration Number: NCT06222619
• Lead Sponsor: Seoul National University Hospital

Brief Summary

Portal vein embolization is often recommended to reduce the risk of postoperative liver failure and mortality. In this retrospective cohort study, researchers investigated the effect of portal vein embolization in patients with resectable perihilar cholangiocarcinoma bismuth type III and IV.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-30
• Primary Completion: 2021-08-30
• Study Completion: 2023-08-30
• Status Verified: 2024-01
• Study First Submitted: 2024-01-11
• Study First Submitted QC: 2024-01-20
• Last Update Submitted: 2024-01-20
• Study First Posted: 2024-01-25
• Last Update Posted: 2024-01-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 136

Inclusion Criteria

1. patients with Bismuth type III or IV stricture on radiological examination, including computed tomography (CT) or magnetic resonance cholangiography
2. patients with perihilar cholangiocarcinoma histologically confirmed by surgical resection or forceps biopsy/brush cytology under endoscopic retrograde cholangiopancreatography or through the percutaneous transhepatic biliary drainage tract.

Exclusion Criteria

1. patients with unresectable perihilar cholangiocarcinoma
2. patients who refused treatment
3. patients with other concomitant malignancies.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
No resection after PVE	Potal vein embilization	No resection of bile duct and associated hemi-liver after portal vein embilzation
Resection after PVE	Potal vein embilization	Resection of bile duct and associated hemi-liver after portal vein embilzation

Primary Outcome Measures

Name	Time	Method
Overall survival	The time from diagnosis until the date of death or last date of follow-up or end of study up to 24 months	Overall survival of each group (A-C).

Secondary Outcome Measures

Name	Time	Method
Recurrence free survival	The time from surgical resection until the date of recurrence or death or last date of follow-up or end of study up to 24 months	Recurrence free survival of patients who underwent surgical resection

Trial Locations

Locations (1)

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of